Prostate Cancer

Tissue-Based Assay Tests Similarly Across Racial Lines in Newly Diagnosed Prostate Cancer

June 13, 2020

In an interview with Targeted Oncology following the American Urological Association Virtual Annual Meeting, Eric A. Klein, MD, discussed the importance of molecular testing in Caucasian and African American patients with newly diagnosed prostate cancer. He also discussed the pros and cons of active surveillance.

Katz Explains the Role of Different Stratification Strategies in Prostate Cancer

June 09, 2020

In an interview with Targeted Oncology, Aaron E. Katz, MD, FACS, discussed the findings from a study of the 17-gene Oncotype DX Genomic Prostate Score.

Morgans Discusses How to Sequence Therapies in Metastatic CRPC

June 08, 2020

Alicia K. Morgans, MD, MPH, discussed treatment and testing strategies for metastatic castration-resistant prostate cancer.

Exploring the Design for Longer Follow-Up of Radium-223 in mCRPC

June 04, 2020

A. Oliver Sartor, MD, discusses the design for an observational study of disease characteristics and outcome of patients with metastatic castration-resistant prostate cancer who received 177Lu-PSMA after receiving radium-223.

Clinically Meaningful Activity Observed With Combination Cabozantinib and Atezolizumab in mCRPC

May 31, 2020

According to findings from the phase 1b COSMIC-021 trial presented at the 2020 ASCO Virtual Scientific Program, cabozantinib and atezolizumab demonstrated clinically meaningful activity in patients with metastatic castration-resistant prostate cancer, including those with high-risk clinical features.

Statistical Analyses Confirm Benefit of Cabazitaxel Over Abiraterone or Enzalutamide in mCRPC

May 31, 2020

Stratified multivariate analysis as well as efficacy from multiple treatment time points confirmed the benefit of cabazitaxel over abiraterone acetate or enzalutamide as a standard treatment in men with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and either of those 2 androgen receptor-targeted agents, according to results presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program.

Darolutamide Demonstrates Improved OS Over Placebo in Phase 3 ARAMIS Trial for Nonmetastatic CRPC

May 31, 2020

Patients with nonmetastatic castration-resistant prostate cancer receiving darolutamide plus androgen deprivation therapy had a 31% reduction for the risk of death compared with placebo and ADT, according to the results of the phase 3 ARAMIS trial’s preplanned final overall survival analysis presented during the 2020 ASCO Virtual Scientific Program.

ctDNA Positivity Correlates With Poor Survival Outcomes in mCRPC

May 31, 2020

"Liquid biopsies continue to gain attention in the field of oncology. The ability to have a rapid, noninvasive test, and one that allows for serial treatment monitoring is imperative for more precise patient care."

Apalutimide Combo Significantly Improves Survival Outcomes in nmCRPC

May 30, 2020

Apalutimide in combination with androgen deprivation therapy led to a significant improvement in overall survival in patients with nonmetastatic castration-resistant prostate cancer in the phase 3 SPARTAN clinical trial.

PyL PET Tracer May Be Superior to Standard Imaging for Prostate Cancer

May 30, 2020

"The CONDOR study met its primary endpoint. Indeed, it well exceeded it. And it demonstrated excellent diagnostic performance of PyL PET in men with biochemically relapsed prostate cancer, even at very low PSA values."